SCHEMBL1920532

SCHEMBL1920532

CCCCCC[C@@]1(n2cnc3c(N)ncnc32)O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 4/20 0.48
ADORA2A P29274 3/20 0.48
EHMT1 Q9H9B1 1/20 0.48
GMPS P49915 1/20 0.48
PI4KA P42356 2/20 0.46
PI4K2B Q8TCG2 2/20 0.46
PI4K2A Q9BTU6 2/20 0.46
PI4KB Q9UBF8 2/20 0.46
SLC28A1 O00337 2/20 0.46
DPP4 P27487 1/20 0.46
MEN1 O00255 1/20 0.46
MAP3K7 O43318 1/20 0.46
SLC28A2 O43868 1/20 0.46
GAPDH P04406 1/20 0.46
MAPK1 P28482 1/20 0.46
ADORA2B P29275 1/20 0.46
ADORA1 P30542 1/20 0.46
STAT6 P42226 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10865960 1.00 ADORA3 (0.48) ADORA3ADORA2AEHMT1GMPSPI4KA
SCHEMBL9231750 0.99 ADORA3 (0.49) ADORA3ADORA2AEHMT1GMPSPI4KA
SCHEMBL29509039 0.96 ADORA3 (0.50) ADORA3ADORA2AEHMT1GMPSPI4KA
SCHEMBL5562015 0.94 ADORA2A (0.46) ADORA3ADORA2AEHMT1GMPSPI4KA
Phosphoric Acid SCHEMBL15210131 0.94 EHMT1 (0.46) ADORA3ADORA2AEHMT1GMPSPI4KA
SCHEMBL28205583 0.92 ADORA3 (0.50) ADORA3ADORA2AGMPSPI4KAPI4K2B
SCHEMBL2534138 0.92 ADORA3 (0.52) ADORA3ADORA2AEHMT1GMPSPI4KA
SCHEMBL25349321 0.91 ADORA3 (0.49) ADORA3ADORA2AGMPSPI4KAPI4K2B
SCHEMBL4884773 0.90 EHMT1 (0.47) ADORA3ADORA2AEHMT1GMPSPI4KA
SCHEMBL10786319 0.90 ADORA3 (0.52) ADORA3ADORA2AGMPSPI4KAPI4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2326953-B1 ADP DETECTION BASED LUMINESCENT PHOSPHOTRANSFERASE OR ATP HYDROLASE ASSAY PROMEGA CORP (US) 2018-03-21 EP disclosed
CN-107406479-A Prevention, the method for mitigating or treating macular degeneration 伊诺泰克制药公司 2017-11-28 CN disclosed
US-8802411-B2 ADP detection based luminescent phosphotransferase or ATP hydrolase assay PROMEGA CORPORATION (US) 2014-08-12 US disclosed
US-20120258480-A1 ADP DETECTION BASED LUMINESCENT PHOSPHOTRANSFERASE OR ATP HYDROLASE ASSAY PROMEGA CORPORATION (US) 2012-10-11 US disclosed
US-8183007-B2 ADP detection based methods using adenylate cyclase and bioluminescence PROMEGA CORPORATION (US) 2012-05-22 US disclosed
EP-2326953-A1 ADP DETECTION BASED LUMINESCENT PHOSPHOTRANSFERASE OR ATP HYDROLASE ASSAY Promega Corporation (US) 2011-06-01 EP disclosed
US-20100075350-A1 ADP detection based luminescent phosphotransferase or ATP hydrolase assay PROMEGA CORPORATION (US) 2010-03-25 US disclosed
WO-2010011607-A1 ADP DETECTION BASED LUMINESCENT PHOSPHOTRANSFERASE OR ATP HYDROLASE ASSAY PROMEGA CORPORATION (US) 2010-01-28 WO disclosed
US-20050009884-A1 Calcium blockers to treat proliferative retinal diseases ALLERGAN, INC. 2005-01-13 US disclosed
US-6380261-B1 ADMINISTERING TO RETINA ANTAGONIST OF THE NMDA RECEPTOR-CHANNEL COMPLEX FOR THERAPY OF PROLIFERATIVE VITREORETINOPATHY RESULTING FROM PENETRATING TRAUMA, RETINAL TEAR, TRACTION DETACHMENT, VITRECTOMY OR INTRAOCULAR SURGERY ALLERGAN SALES, INC. 2002-04-30 US disclosed
EP-0996453-A1 METHODS FOR THE INHIBITION OF NEURONAL ACTIVITY BY LOCAL DELIVERY OF ADENOSINE Mohler, Hanns (CH) 2000-05-03 EP disclosed
WO-1998058653-A1 METHODS FOR THE INHIBITION OF NEURONAL ACTIVITY BY LOCAL DELIVERY OF ADENOSINE MOHLER HANNS (CH) 1998-12-30 WO disclosed
WO-1995011681-A1 HUMAN ADENOSINE RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1995-05-04 WO disclosed